Study says inflammation seen in earliest stages of Parkinson’s disease, and it is different between men and women

BIRMINGHAM, Ala. – New research shows evidence of inflammation in the blood of Parkinson’s disease patients during the earliest stages of the disease, lending support to theories that inflammation is a major driver of PD. The findings, from researchers at the Alabama Udall Center at the University of Alabama at Birmingham, were published April 13 in npj Parkinson’s Disease, part of the Nature Partner Journal series in partnership with the Parkinson’s Foundation.

UAB is one of six National Institutes of Health-funded Morris K. Udall Centers of Excellence in Parkinson’s Disease Research.

“There is a growing body of evidence suggesting that inflammation plays a major role in the development and progression of Parkinson’s disease,” said David Standaert, M.D., Ph.D, chair of the UAB Department of Neurology in the School of Medicine and senior author of the study. “This is one of the first studies to pinpoint inflammation in the blood in patients with early PD, supporting the idea that systemic immune system activation is present early in PD.”

Standaert also says the study revealed interesting differences in the inflammation signature in women compared to men. While PD is much more common in men, there is increasing evidence that there are also other differences between the sexes in the symptoms and course of the disease. The findings bolster the idea that different approaches to treatment are needed based on the sex of the patient.

The study enrolled 34 patients, 21 males and 13 females. Eighteen had early Parkinson’s disease and 16 were healthy age-matched controls. Those with PD were within two years of symptom onset and had not begun taking anti-Parkinsonian medications.

“The majority of studies into the role of inflammation in PD have been conducted in patients with long-standing disease and wide variations in disease severity. Most had also received a number of different treatments for the disease,” said first author Samantha Carlisle, Ph.D., with the UAB Center for Clinical and Translational Science. “We looked at newly diagnosed patients to improve our understanding of whether inflammation is present early on, or develops as the disease progresses.”

The study examined blood monocytes, cells that are derived from bone marrow, which have been linked to the development of PD. They appear to have a central role in immune signaling through engulfing, processing and presenting foreign antigens for recognition by the adaptive arm of the immune system, thus turning on the immune system in the presence of PD.

The research team used molecular approaches to examine the state of activation of peripheral blood monocytes in human PD. They found evidence of inflammation in blood monocytes, with an unexpectedly strong effect in women.

“We found that there was a striking effect of sex on monocyte gene expression, with increased inflammatory activation of monocytes in females with PD,” said Hongwei Qin, M.D., Ph.D., associate professor in the UAB Department of Cell, Integrated and Developmental Biology. “In males, the activation patterns were more diverse. This indicates the importance of systemic monocyte activation in PD, and the importance of studies which examine how men and women respond in different ways to the disease.”

The Parkinson’s Foundation estimates there are nearly one million people living with Parkinson’s disease in the United States and more than 10 million worldwide. Men are 1.5 times more likely to have PD than women.

“In addition to the greater frequency of PD in men, there are other differences between men and women, in frequency of tremor and imbalance, response to medications and cognitive features,” Standaert said. “Identification of an inflammatory signature in the blood of PD patients opens the door to novel approaches to both biomarkers and treatment as well as an increased understanding that therapies for PD need to be tailored to the patient.”

Standaert says the study of inflammation in Parkinson’s disease is a major focus of the Alabama Udall Center.

Additional co-authors are R. Curtis Hendrickson, Richard E. Kennedy, Ph.D., Zhaoqi Yan, Talene A. Yacoubian, M.D., Etty N. Benveniste, Ph.D., and Ashley Harms, Ph.D., Alabama Udall Center: Jordana E. Muwanguzi, and Elliot J. Lefkowitz,, Ph.D., UAB CCTS; Andrew B. West, Ph.D., Duke University.

Supported by the Alabama Morris K. Udall Center of Excellence in Parkinson Disease Research (P50NS108675), NIH grant P20NS092530, and by the UAB Center for Clinical and Translational Science Grant Number UL1TR003096 from the National Center for Advancing Translational Sciences.

About UAB

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham, a part of the University of Alabama System, is an internationally renowned research university and academic medical center with over $600 million in research awards annually, as well as Alabama’s largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB’s mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at www.uab.edu.

EDITOR’S NOTE: The University of Alabama at Birmingham is one of three doctoral research universities in the University of Alabama System. In your first reference to our institution, please use University of Alabama at Birmingham and UAB on subsequent references.

VIDEO: www.youtube.com/uabnews TEXT: www.uab.edu/news TWEETS: www.twitter.com/uabnews